Q: Bristol Myers(BMY)has had a very good run in the past 12 months, but revenue growth and earnings growth are going in the wrong direction. The company seems expensive at current levels. Is drug pipeline hope causing the premium and is it warranted or is the company just over-priced?
Thanks!
Thanks!